Frontline Palbociclib Opens the Door to Subsequent CDK4/6 Inhibition in Metastatic Breast Cancer
Jairam Krishnamurthy, MD, FACP, discusses the selective use of CDK4/6 inhibitors after prior progression on these agents in patients with breast cancer.